Active Biotech
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
ACTI | ST
Overview
Corporate Details
- ISIN(s):
- SE0001137985 (+2 more)
- LEI:
- 549300OJ44CLMRU8YE43
- Country:
- Sweden
- Address:
- Scheelevägen 22, 223 63 Lund
Description
Active Biotech is a biotechnology company that develops pharmaceuticals for specialist indications with high medical need, focusing on oncology and inflammatory eye disorders. The company leverages its knowledge of the immune system to advance its clinical pipeline. Its portfolio includes fully-owned projects such as tasquinimod for hematological cancers, including multiple myeloma and myelofibrosis, and laquinimod, developed as eye drops for non-infectious uveitis. Additionally, the company has licensed projects, including naptumomab, which is being developed in partnership with NeoTX for the treatment of solid tumors.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2017-08-10 08:32 | English | PDF • 454.1 KB | |||
| 2017-06-19 15:31 |
Helén Tuvesson new CEO of Active Biotech AB from July 1, 2017
|
English | PDF • 123.8 KB | ||
| 2017-06-19 15:31 |
Helén Tuvesson ny VD för Active Biotech AB från 1 juli 2017
|
Swedish | PDF • 124.5 KB | ||
| 2017-06-16 08:31 |
Annual General Meeting of Active Biotech AB
|
English | PDF • 267.3 KB | ||
| 2017-06-16 08:31 |
Årsstämma i Active Biotech AB
|
Swedish | PDF • 188.5 KB | ||
| 2017-05-18 14:31 | English | PDF • 266.8 KB | |||
| 2017-05-18 14:30 | Swedish | PDF • 8.8 MB | |||
| 2017-05-17 11:50 |
Active Biotech: Notice of Annual General Meeting of Shareholders
|
English | PDF • 34.8 KB | ||
| 2017-05-17 11:50 |
Active Biotech: Kallelse till årsstämma
|
Swedish | PDF • 30.3 KB | ||
| 2017-05-05 20:00 |
Teva och Active Biotech tillkännager att det primära kliniska målet i CONCERTO-…
|
Swedish | PDF • 212.4 KB | ||
| 2017-05-05 20:00 |
Teva and Active Biotech Announce CONCERTO trial of Laquinimod in RRMS Did Not M…
|
English | PDF • 194.1 KB | ||
| 2017-04-27 08:31 | Swedish | PDF • 373.6 KB | |||
| 2017-04-27 08:31 | English | PDF • 371.5 KB | |||
| 2017-04-12 13:31 |
Active Biotech: FDA grants Orphan Drug Designation for tasquinimod for the trea…
|
English | PDF • 149.7 KB | ||
| 2017-04-12 13:31 |
Active Biotech: FDA beviljar särläkemedelsstatus för tasquinimod för behandling…
|
Swedish | PDF • 126.8 KB |
Automate Your Workflow. Get a real-time feed of all Active Biotech filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Active Biotech
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Active Biotech via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-01-10 | Peter Thelin | Other | Other | 164,638,960 | 8,231,948.00 SEK |
| 2024-11-15 | Hans Kolam | Other | Other | 19,800 | 990.00 SEK |
| 2022-09-05 | Aleksandar Danilovski | Other | Buy | 26,672 | 26,672.00 SEK |
| 2022-04-22 | Helen Tuvesson Andersson | Other | Buy | 2,665 | 3,102.86 SEK |
| 2022-04-21 | Helen Tuvesson Andersson | Other | Buy | 37,335 | 41,767.60 SEK |
| 2021-06-17 | Aleksandar Danilovski | Other | Buy | 40,000 | 60,000.00 SEK |
| 2021-06-01 | Michael Shalmi | Other | Buy | 175,000 | 259,437.50 SEK |
| 2021-04-27 | Helen Tuvesson Andersson | Other | Buy | 10,411 | 16,657.60 SEK |
| 2021-04-27 | Helena Eriksson | Other | Buy | 10,000 | 14,460.00 SEK |
| 2021-04-27 | Helen Tuvesson Andersson | Other | Buy | 1,041 | 1,665.60 SEK |
Peer Companies
